BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-67@pharmaconomics
DTSTAMP:20260707T033821Z
DTSTART;VALUE=DATE:20260831
DTEND;VALUE=DATE:20260901
SUMMARY:RHHBY Phase 3 — Sefaxersen (RO7434656)
DESCRIPTION:Phase 3 trial results for Sefaxersen (RO7434656) in Primary IgA Nephropathy are due Aug 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT05797610\n\nTrack it: https://pharmaconomics.com/e/67
URL:https://pharmaconomics.com/e/67
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RHHBY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR